Loading
Ryvu Therapeutics
Ryvu Therapeutics is a Poland-based biotechnology company running 5 late-stage cancer trials of RVU120, MEN1703 and Glofitamab in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms and hodgkin lymphoma.
Also called: Ryvu Therapeutics SA
Overview
Ryvu Therapeutics, based in Krakow, Poland, is a biotechnology company. A clinical-stage drug discovery and development company focused on novel small-molecule therapies addressing emerging targets in oncology. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials, testing RVU120, MEN1703, Glofitamab and Ruxolitinib in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms, hodgkin lymphoma and myeloproliferative neoplasms. The largest, NCT06397313 (RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis), plans to enrol 230 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Krakow, PL
Scorecard
All companies#330of 1245 companies, score 12
- phase 1/2 +2
- targets +2
- modalities +2
- registry trials +6
0 approved, 0 in phase 3, 2 earlier, 1 targets, 8 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Products
2Phase 2small molecule (kinase inhibitor)
MEN1703 is an experimental small molecule (kinase inhibitor) from Ryvu Therapeutics in phase 2 trials for hodgkin lymphoma, aimed at FLT3.
Phase 2Small-molecule inhibitor
RVU120 is a small-molecule inhibitor from Ryvu Therapeutics SA, in registered phase 2 trials for acute myeloid leukaemia.
Connected
9Similar pages
- TargetSLX4
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Acute myeloid leukaemia.
- JournalCurrent hematologic malignancy reports
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Hodgkin lymphoma, Acute myeloid leukaemia.
- TargetDDX41
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Acute myeloid leukaemia.
- JournalLeukemia & lymphoma
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Hodgkin lymphoma, Acute myeloid leukaemia.
- TrialA First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Shares Myelodysplastic syndromes / neoplasms (MDS), Hodgkin lymphoma, Acute myeloid leukaemia.
- JournalLeukemia research
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Acute myeloid leukaemia.
- TargetFANCC
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Acute myeloid leukaemia.
- TargetGATA2
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Acute myeloid leukaemia.
cancers
drugs
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
ryvu.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/